ACAD ACADIA PHARMACEUTICALS INC
Price Chart
Executive Summary
Multiple C-suite executives at Acadia Pharmaceuticals, including the CEO, CFO, and other senior officers, conducted open-market share sales totaling approximately $504,000 over a two-day period, concurrent with the exercise of stock options. The sales represent a coordinated liquidity event following derivative exercises, but the dollar amount is small relative to the company's $3.8B market cap.
Key Financial Metrics
Actionable Insight
This cluster reflects routine option exercise and diversification activity by executives, not a signal of fundamental concern. Traders should monitor for any follow-up filings or news around earnings or pipeline updates, but no immediate action is warranted based on this activity.
Key Facts
- CEO Catherine Owen Adams sold $249,932 worth of shares, CFO Mark Schneyer sold $158,332, and other C-suite executives sold an additional $95,766 in open-market transactions.
- All sales were preceded by or concurrent with the exercise of stock options (M-coded transactions), indicating pre-planned option monetization rather than discretionary selling of held shares.
- Total open-market sale value across all insiders: ~$504,000 over two days.
- Total value represents only 0.013% of Acadia's $3.8B market cap — well below the 0.1% threshold for materiality.
- No negative corporate news or guidance changes were reported alongside these transactions.
Financial Impact
$504,000 in open-market sales over two days (0.013% of market cap)
Risk Factors
- Perception risk: Concentrated insider selling, even if routine, could be misinterpreted by retail investors as negative sentiment.
- Liquidity timing: If these sales were accelerated ahead of potential bad news, it could raise questions — though no such catalyst is currently evident.
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (20 trades, 7d window) | cluster-ACAD-1774569644055 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 6, 2026
4w ago
|
8-K
| $22.56 $21.43 | ▲ +5.01% | ▲ +8.14% | $21.84 (+3.19%) |
|
May 4, 2026
5w ago
|
Insider Cluster
| $22.19 $21.52 | ▼ −3.02% | ▼ −8.66% | $21.84 (−1.58%) |
|
Mar 25, 2026
11w ago
|
Insider Cluster
| $22.01 $22.11 | ▲ +0.45% | ▼ −7.41% | $21.84 (−0.77%) |
|
Mar 5, 2026
13w ago
|
8-K
| $22.40 $22.20 | ▼ −0.89% | ▲ +2.90% | $21.84 (−2.50%) |
|
Feb 25, 2026
14w ago
|
8-K
| $24.64 $21.47 | ▼ −12.87% | ▼ −6.46% | $21.84 (−11.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access